AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 MAY 16 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - A new conjugate of the capsular polysaccharide of Salmonella typhi, Vi, bound to nontoxic recombinant Pseudomonas aeruginosa exotoxin A (rEPA) offers 90% efficacy in children two to five years old, according to a report in the New England Journal of Medicine.
"Typhoid fever is common in developing countries," noted F.Y. Lin and colleagues at the U.S. National Institutes of Health. "The licensed typhoid vaccines confer only about 70% immunity, do not protect young children, and are not used for routine vaccination."
Lin and team compared the Vi-rEPA vaccine with placebo in 11,091 Vietnamese children in a randomized, double-blind trial. Of the 5,525 children who received V-rEPA, four developed typhoid during the 27-month follow-up period. Of the 5,566 children who received placebo, 47 developed typhoid, as determined by isolating S. typhi from blood cultures.
The researchers estimated an efficacy of 91.5% by comparing the attack rate of typhoid in the vaccine group with that in the placebo group.
No serious adverse effects were reported ("The efficacy of a Salmonella typhi Vi conjugate vaccine in two- to five-year-old children," N Engl J Med, 2001;344(17):1263-1269).
The second ...
Source: HighBeam Research, Conjugate Vaccine Has 90% Efficacy In Young Children.(Brief Article)